These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 11225566

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics.
    Stout SM, Nielsen J, Bleske BE, Shea M, Brook R, Kerber K, Welage LS.
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):373-9. PubMed ID: 20705902
    [Abstract] [Full Text] [Related]

  • 3. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
    Saito M, Kawana J, Ohno T, Hanada K, Kaneko M, Mihara K, Shiomi M, Nagayama M, Sumiyoshi T, Ogata H.
    Biol Pharm Bull; 2010 Dec; 33(8):1378-84. PubMed ID: 20686235
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism.
    Nardotto GHB, Coelho EB, Paiva CE, Lanchote VL.
    J Clin Pharmacol; 2017 Jun; 57(6):760-769. PubMed ID: 28114735
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency.
    Gehr TW, Tenero DM, Boyle DA, Qian Y, Sica DA, Shusterman NH.
    Eur J Clin Pharmacol; 1999 Jun; 55(4):269-77. PubMed ID: 10424319
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
    Sehrt D, Meineke I, Tzvetkov M, Gültepe S, Brockmöller J.
    Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
    Henderson LS, Tenero DM, Baidoo CA, Campanile AM, Harter AH, Boyle D, Danoff TM.
    Am J Cardiol; 2006 Oct 02; 98(7A):17L-26L. PubMed ID: 17023228
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Stereoselective disposition of carvedilol is determined by CYP2D6.
    Zhou HH, Wood AJ.
    Clin Pharmacol Ther; 1995 May 02; 57(5):518-24. PubMed ID: 7768074
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound.
    Neugebauer G, Akpan W, Kaufmann B, Reiff K.
    Eur J Clin Pharmacol; 1990 May 02; 38 Suppl 2():S108-11. PubMed ID: 1974498
    [Abstract] [Full Text] [Related]

  • 20. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.
    Giessmann T, Modess C, Hecker U, Zschiesche M, Dazert P, Kunert-Keil C, Warzok R, Engel G, Weitschies W, Cascorbi I, Kroemer HK, Siegmund W.
    Clin Pharmacol Ther; 2004 Mar 02; 75(3):213-22. PubMed ID: 15001973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.